Results For "Apellis-Pharmaceuticals"

1 News Found

Biogen to buy Apellis Pharmaceuticals for $5.6B in rare disease and immunology push

News | April 02, 2026

Biogen to buy Apellis Pharmaceuticals for $5.6B in rare disease and immunology push

The acquisition brings two commercialized, differentiated medicines—EMPAVELI and SYFOVRE —to Biogen’s growth portfolio

Latest Stories

Lupin launches Atharv ability neuro-rehabilitation centre in Delhi

Alembic Pharma Q4 revenue rises to Rs. 1,848 crore

WFNS opens doors to industry in landmark Neurosurgery Innovation Pact with Time Med

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews

AI will eliminate 70-80% of current pharma commercial processes: Dushyant Sapre, Founder and CEO, SwishX

AI will eliminate 70-80% of current pharma commercial processes: Dushyant Sapre, Founder and CEO, SwishX

Dushyant Sapre Founder and CEO, SwishX

Agentic AI poised to reshape pharma operations beyond pilot-stage adoption: Duraisamy Rajan Palani, Founder & CEO, Archimedis Digital

Agentic AI poised to reshape pharma operations beyond pilot-stage adoption: Duraisamy Rajan Palani, Founder & CEO, Archimedis Digital

Duraisamy Rajan Palani Founder and CEO, Archimedis Digital

Patient-centric innovation driving fight against neglected diseases: Sanjay Sarin, Continental Lead Asia and South Asia Director, DNDi

Patient-centric innovation driving fight against neglected diseases: Sanjay Sarin, Continental Lead Asia and South Asia Director, DNDi

Sanjay Sarin, Continental Lead Asia and South Asia Director, DNDi

Packaging